E.05.02 Metabolic alterations and their background in patients with affective disorders

Kahl, K.G.; Lampen-Inkamp, S.; Claassen, B.; Peschel, Thomas; Schik, Gesa

doi:10.1016/s0924-977x(10)70248-0

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, mental health disorders such as depression, mood disorders, schizophrenia, sleep disorders, bipolar behavior disorders, and autism are related to significant metabolic changes, either due to weight gain or loss caused by sedentary lifestyles, or psychophysiological disorders and/or comorbidity with congenital diseases ( Table 9 ) [ 43 ].…”

Section: Resultsmentioning

confidence: 99%

“…This is an alteration associated with metabolic syndrome, relating comorbidity with diabetes mellitus type 2 and cardiovascular disorders [43]. Direct relationship between physical and metabolic alterations, the stress regulatory system and the appetite activator, caused by the body's energy deficiency in the major depressive disorder due to imbalance of the hypothalamus-pituitary-adrenal gland, the concentration of hormones, and appetite [33,55].…”

Section: Depression Mood Disordersmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review

Sepúlveda-Lizcano,

Arenas-Villamizar,

Jaimes-Duarte

et al. 2023

EJIHPE

View full text Add to dashboard Cite

This review aimed to investigate the metabolic alterations associated with psychopharmacological treatment of neuropsychiatric disorders, which can significantly impact patients’ physical health and overall quality of life. The study utilized the PRISMA methodology and included cross-sectional, retrospective studies, and randomized clinical trials from reputable databases like SCOPUS, CLARIVATE, SCIENCE DIRECT, and PUBMED. Out of the 64 selected studies, various psychotropic drug classes were analyzed, including antidepressants, anticonvulsants, and antipsychotics. Among the antidepressants, such as amitriptyline, Imipramine, and clomipramine, weight gain, constipation, and cardiovascular effects were the most commonly reported metabolic adverse effects. SSRI antidepressants like Fluoxetine, Sertraline, Citalopram, Escitalopram, and Paroxetine exhibited a high prevalence of gastrointestinal and cardiac alterations. Regarding anticonvulsants, valproic acid and Fosphenytoin were associated with adverse reactions such as weight gain and disturbances in appetite and sleep patterns. As for antipsychotics, drugs like Clozapine, Olanzapine, and Risperidone were linked to weight gain, diabetes, and deterioration of the lipid profile. The findings of this review emphasize the importance of continuous monitoring for adverse effects, particularly considering that the metabolic changes caused by psychopharmacological medications may vary depending on the age of the patients. Future research should focus on conducting field studies to further expand knowledge on the metabolic effects of other commonly prescribed psychotropic drugs. Overall, the study highlights the significance of understanding and managing metabolic alterations induced by psychopharmacological treatment to enhance patient care and well-being.

show abstract

Section: Resultsmentioning

confidence: 99%